Our Portfolio

Current and Prior Investments

Strategy:

AtomVie

https://www.atomvie.com/

Investment Date: 2022

Read more
Health Outlook

https://www.healthoutlook.com/

Investment Date: 2022

Read more
Xcell Biosciences

https://www.xcellbio.com/

Investment Date: 2022

Read more
Ellie Diagnostics

https://elliediagnostics.com/

Investment Date: 2021

Read more
Antios Therapeutics

https://www.antiostherapeutics.com/

Investment Date: 2021

Read more
Jasper Therapeutics

https://www.jaspertherapeutics.com/

Investment Date: 2021

Read more
Caribou Biosciences

https://www.cariboubio.com/

Investment Date: 2021

Read more
Ribon Therapeutics

https://ribontx.com/

Investment Date: 2021

Read more
Arch Oncology

https://archoncology.com/

Investment Date: 2021

Read more
Immunocore

https://www.immunocore.com/

Investment Date: 2020

Read more
Sentynl Therapeutics

http://www.sentynl.com/

Investment Date: 2015

Read more
Amber Ophthalmics

https://www.amberophthalmics.com/

Investment Date: 2020

Read more
Eyevance Pharmaceuticals

https://eyevance.com/

Investment Date: 2017

Read more
Sebela Pharmaceuticals

https://sebelapharma.com/

Investment Date: 2018

Read more
Saol Therapeutics

https://saolrx.com/

Investment Date: 2015

Read more

AtomVie

https://www.atomvie.com/

Investment Date: 2022

Global contract development and manufacturing organization for radiotherapeutics.

Health Outlook

https://www.healthoutlook.com/

Investment Date: 2022

Health prediction company utilizing proteomics and advanced statistical techniques to better predict and improve health outcomes.

Xcell Biosciences

https://www.xcellbio.com/

Investment Date: 2022

Commercial-stage life science company dedicated to bringing an innovative primary cell control solution to the immunotherapy market to support research, drug discovery, and cell manufacturing.

Ellie Diagnostics

https://elliediagnostics.com/

Investment Date: 2021

Disruptive animal health provider delivering innovative diagnostic solutions to veterinarians and pet owners across the United States.

Antios Therapeutics

https://www.antiostherapeutics.com/

Investment Date: 2021

Clinical-stage biotechnology company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV).

Jasper Therapeutics

https://www.jaspertherapeutics.com/

Investment Date: 2021

Clinical-stage biotechnology company focused on enabling cures with hematopoietic stem cell therapies.

Merged with Amplitude Healthcare Acquisition Corporation in 2021

Caribou Biosciences

https://www.cariboubio.com/

Investment Date: 2021

Clinical-stage biotechnology company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.

Completed IPO in 2021

Ribon Therapeutics

https://ribontx.com/

Investment Date: 2021

Clinical-stage biotechnology company pursuing the development of novel small molecules that target cancer through its dependency on stress support pathways.

Arch Oncology

https://archoncology.com/

Investment Date: 2021

Clinical-stage immuno-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer.

Immunocore

https://www.immunocore.com/

Investment Date: 2020

Clinical-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease.

Completed IPO in 2021

Sentynl Therapeutics

http://www.sentynl.com/

Investment Date: 2015

Commercial-stage specialty pharmaceutical company focused on pain management and adjacent specialty therapeutics areas.

Acquired by Zydus in 2017

Amber Ophthalmics

https://www.amberophthalmics.com/

Investment Date: 2020

Clinical-stage ophthalmic company focused on novel therapeutics to address unmet medical needs, providing for the restoration, preservation, and improvement of patient vision and quality of life.

Eyevance Pharmaceuticals

https://eyevance.com/

Investment Date: 2017

Commercial-stage specialty ophthalmic company focused on innovative and impactful branded prescription products targeting the anterior segment of the eye.

Acquired by Santen in 2020

Sebela Pharmaceuticals

https://sebelapharma.com/

Investment Date: 2018

Commercial-stage specialty pharmaceutical company focused on gastrointestinal, dermatological, and women’s health products.

Saol Therapeutics

https://saolrx.com/

Investment Date: 2015

Clinical-stage therapeutics company focused on the central nervous system (CNS), orphan diseases, and conditions with high unmet medical need.